Full-Time

Lead Maintenance and Utilities Technician

Posted on 8/15/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$40 - $60/hr

Sanford, NC, USA

In Person

Initially on construction site; 100% on-site role in Sanford, NC with up to 5% travel; production schedule may shift to 2-2-3 day cycle.

Category
Mechanical Engineering (2)
,
Requirements
  • Minimum of 4 years relevant maintenance experience and High School diploma or equivalent.
  • Associates or Bachelor’s degree in a related field is a plus.
  • Minimum of 4 years’ experience performing mechanical in both process areas and in a laboratory environment.
  • Minimum of 2 years’ experience within a GMP and/or other highly regulated environment
  • Experience with CMMS platforms, such as D365 EAM, SAP PM, Maximo or other CMMS platforms preferred.
  • Ability to work collaboratively with our clients to promote excellence in customer service.
  • Strong communication and organizational skills.
  • Excellent attention to detail and data integrity.
  • Results-oriented and able to navigate ambiguity, you set clear outcomes, track progress, follow through on commitments, and ensure your actions lead to measurable results that advance organizational objectives.
  • Respond promptly, take accountability, and manage tasks efficiently.
  • Adapt to change with clarity, patience, and understanding, guiding teams through evolving challenges.
  • Exhibit strong organizational skills, attention to detail, and a solid work ethic while demonstrating cultural sensitivity and the ability to foster alignment in a global environment.
  • Communicate with care by actively listening and considering others' perspectives, fostering productive, engaging interactions, and managing relationships with kindness.
  • Embrace personal growth through continuous learning and knowledge sharing, maintaining a growth mindset.
  • Promote inclusive collaboration by respecting diverse perspectives and creating a welcoming work environment.
  • Contribute positively by recognizing achievements and encouraging a healthy work-life balance.
  • Collaborate with respect, integrity, and humility, prioritizing collective success over individual gain.
  • Resourceful and proactive, challenge the status quo, drive innovation, and develop creative solutions.
  • Apply an enterprise-wide, holistic mindset, working beyond siloed thinking to deliver cohesive, integrated solutions.
Responsibilities
  • Perform scheduled inspections and preventive maintenance on bioprocessing equipment (e.g., bioreactors, centrifuges, filtration units).
  • Diagnose equipment malfunctions and execute timely, effective repairs.
  • Actively support the installation and startup of new equipment, ensuring seamless integration with control systems (PLC, SCADA, DCS); assist with mechanical installation and qualification activities.
  • Coordinate maintenance activities with internal stakeholders (e.g., manufacturing and laboratory teams) to minimize operational disruptions.
  • Demonstrate a strong commitment to quality, safety, and compliance.
  • Provide hands-on support for the startup, commissioning, and turnover of new systems across the site.
  • Maintain accurate records to support audits and ensure compliance with GMP and FDA regulations.
  • Coordinate maintenance activities with internal and external stakeholders to minimize disruptions, escalate issues.
  • Collaborate closely with process engineers, quality assurance, and manufacturing staff to ensure seamless operations.
  • Resolve current issues in a timely manner, while proactively documenting root causes and recommending long-term solutions to prevent recurrence.
Desired Qualifications
  • Associates or Bachelor’s degree in a related field is a plus.
  • Experience with CMMS platforms, such as D365 EAM, SAP PM, Maximo or other CMMS platforms preferred.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE